Candriam Luxembourg S.C.A. cut its stake in shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) by 12.9% during the second quarter, Holdings Channel reports. The fund owned 202,000 shares of the biopharmaceutical company’s stock after selling 30,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Halozyme Therapeutics were worth $1,743,000 as of its most recent SEC filing.
Several other institutional investors have also recently modified their holdings of HALO. Meeder Asset Management Inc. purchased a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $155,000. Fisher Asset Management LLC boosted its position in shares of Halozyme Therapeutics by 2.4% in the second quarter. Fisher Asset Management LLC now owns 725,011 shares of the biopharmaceutical company’s stock valued at $6,583,000 after buying an additional 17,231 shares during the last quarter. Panagora Asset Management Inc. boosted its position in shares of Halozyme Therapeutics by 15.5% in the first quarter. Panagora Asset Management Inc. now owns 742,510 shares of the biopharmaceutical company’s stock valued at $7,032,000 after buying an additional 99,396 shares during the last quarter. Bellevue Group AG purchased a new position in shares of Halozyme Therapeutics during the first quarter valued at approximately $3,011,000. Finally, A.R.T. Advisors LLC boosted its position in shares of Halozyme Therapeutics by 12.4% in the first quarter. A.R.T. Advisors LLC now owns 120,238 shares of the biopharmaceutical company’s stock valued at $1,138,000 after buying an additional 13,300 shares during the last quarter. Institutional investors own 80.41% of the company’s stock.
Halozyme Therapeutics Inc. (NASDAQ:HALO) traded up 1.32% during midday trading on Monday, reaching $12.24. 1,283,416 shares of the company’s stock were exchanged. The stock’s market cap is $1.57 billion. Halozyme Therapeutics Inc. has a 12 month low of $6.96 and a 12 month high of $18.65. The firm has a 50 day moving average of $10.88 and a 200-day moving average of $9.99.
Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.06. The business had revenue of $33.30 million for the quarter, compared to analysts’ expectations of $29.94 million. Halozyme Therapeutics had a negative net margin of 44.90% and a negative return on equity of 234.15%. The firm’s revenue for the quarter was down 23.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.02 earnings per share. On average, equities research analysts predict that Halozyme Therapeutics Inc. will post ($0.91) earnings per share for the current year.
Several brokerages have recently commented on HALO. Piper Jaffray Cos. boosted their target price on shares of Halozyme Therapeutics from $15.00 to $18.00 and gave the company an “overweight” rating in a research report on Friday, September 16th. Wells Fargo & Co. restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, September 8th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $11.00 price target on shares of Halozyme Therapeutics in a report on Monday, June 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $16.11.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.